DMAC (DiaMedica Therapeutics) Operating Cash Flow per Share : $-0.50 (TTM As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Operating Cash Flow per Share?

DiaMedica Therapeutics's operating cash flow per share for the three months ended in Sep. 2024 was $-0.11. DiaMedica Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.50.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 0.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 8.00% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for DiaMedica Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

DMAC' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -60.7 Med: 1.9 Max: 42.3
Current: 0.6

During the past 13 years, DiaMedica Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.30% per year. The lowest was -60.70% per year. And the median was 1.90% per year.

DMAC's 3-Year OCF Growth Rate is ranked worse than
54.15% of 1193 companies
in the Biotechnology industry
Industry Median: 3.6 vs DMAC: 0.60

DiaMedica Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for DiaMedica Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Operating Cash Flow per Share Chart

DiaMedica Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.76

-0.59

-0.44

-0.58

DiaMedica Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.13	-0.10	-0.18	-0.12	-0.11

Competitive Comparison of DiaMedica Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, DiaMedica Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Price-to-Operating-Cash-Flow falls into.

DiaMedica Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

DiaMedica Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-18.728	/	32.567
	=	-0.58

DiaMedica Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Sep. 2024 )	=	Cash Flow from Operations (Q: Sep. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
	=	-4.47	/	42.752
	=	-0.10

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.50

DiaMedica Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

DiaMedica Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website

https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Executives

Jan Stahlberg	10 percent owner	C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Koch Thomas Von	10 percent owner	TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Scott Kellen	officer: CFO and Secretary	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill	10 percent owner	SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls	director, officer: President and CEO	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto	10 percent owner	394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke	officer: Chief Business Officer	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt	10 percent owner	C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Ab Tomenterprise	10 percent owner	C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves	officer: SVP Clinical Development Oper.	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305